2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2119 CD49d is a prognostic marker for time to first treatment in newly diagnosed CLL and MBL independent of CLL-international prognostic index (CLL-IPI)

Yuan Yao, MD, MS, Tait D Shanafelt, MD2, Kari G Rabe, MS3, Saad Kenderian, M.B., Ch.B.4, Yucai Wang, MD, PhD5, Paul J. Hampel, MD6, Lindsey Elizabeth Roeker, MD7, Curtis A. Hanson, MD8, Min Shi, M.D.9, Esteban Braggio, PhD10, Susan L. Slager, PhD11, Neil E Kay, M.D.12, Sameer A. Parikh, MBBS13
1 Mayo Clinic, Rochester, Minnesota, United States
2 Stanford University, Stanford, California, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States

Background: Chronic lymphocytic leukemia (CLL) is a highly heterogeneous disease, necessitating accurate prognostic tools. Despite progress, existing prognostic tools for predicting time from diagnosis to treatment lack sufficient accuracy to allow reliable counseling of individual CLL patients. The CLL International Prognostic Index (CLL-IPI), integrating age, clinical stage, β2-microglobulin, IGHV mutational status, and TP53 aberration, is the current benchmark for risk stratification. CD49d, a component of the integrin heterodimer α4β1, facilitates interaction of CLL B-cells with the microenvironment and mediates proliferation signals. CD49d positivity has been found to predict time to first treatment (TTFT) independent of other established CLL prognostic markers; however, CD49d has not yet been incorporated into integrated prognostic tools such as CLL-IPI, as it was not available in the datasets from which those tools were derived. We sought to determine whether CD49d at diagnosis predicts outcomes independent of the CLL-IPI in patients with CLL and its precursor, high-count monoclonal B-cell lymphocytosis (HC-MBL).

Methods: We used the Mayo Clinic CLL Database to identify patients with newly diagnosed CLL and HC-MBL consented within 2 years of diagnosis. CD49d levels were quantitated by flow cytometry, and a cutoff of 30% was used to determine positivity. We used Chi-squared or Fisher’s exact tests to compare discrete variables and the Kruskal Wallis test for continuous variables. TTFT was calculated from date of diagnosis to date of first treatment or date last known to be untreated. Overall survival (OS) was calculated from date of diagnosis to date of death or date last known to be alive. We used Cox regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between TTFT and OS and CD49d.

Results:

We identified 2,197 newly diagnosed patients (1,631 CLL and 566 HC-MBL) who had undergone CD49d testing with results available at the time of diagnosis. The median age at diagnosis was 64 years (range 24-95); 1449 (66%) were male, 926 (42.1%) had unmutated IGHV genes, and 9.5% of those who were tested had TP53 disruption. Based on CLL-IPI, 983 (45%) patients had low risk, 708 (32%) had intermediate risk, and 506 (23%) had high/very high risk. Median CD49d percentage was 7% (range 0-100). With respect to CD49d status, 1461 (66%) were CD49d negative and 736 (34%) were CD49d positive.

The median follow-up for the cohort was 7.4 years. A total of 856 patients started therapy (740 CLL and 116 MBL), and 614 patients died (445 CLL and 169 MBL). The TTFT was significantly shorter for patients with positive CD49d compared to negative CD49d at diagnosis (median 3.6 vs 15.6 years). On multivariable analysis, the following characteristics were associated with a shorter TTFT: TP53 aberration (HR: 1.8, 95%CI: 1.4-2.2), unmutated IGHV (HR: 2.9, 95%CI: 2.5-3.4), β2-microglobulin > 3.5 (HR: 2.2, 95%CI: 1.9-2.6), diagnosis age ≤ 65 (HR: 1.25, 95%CI: 1.1-1.4), Rai stage 1-4 (HR: 2.7, 95%CI: 2.3-3.1), CD49d positivity (HR: 1.6, 95%CI: 1.4-1.8) (all comparisons, P < 0.01). Compared with the low-risk group, higher CLL-IPI risk was associated with progressively shorter TTFT: HR 3.1 (95%CI: 2.6-3.6) for intermediate, 5.8 (95%CI: 4.8-7.1) for high, and 10.7 (95%CI: 8.1-11.2) for very high-risk group. In multivariable analyses adjusted for CLL-IPI, positive CD49d remained independently associated with a shorter TTFT (HR: 2.0, 95%CI: 1.7-2.3, P < 0.0001). CD49d positivity was associated with shorter OS on univariate analysis; however, the association was no longer significant after adjusting for CLL-IPI.

Conclusions:

CD49d positivity at the time of diagnosis is a robust predictor of TTFT independently of the CLL-IPI for individuals with newly diagnosed CLL and HC-MBL. Additional analysis evaluating how CD49d status may be integrated into the CLL-IPI to enhance its prognostic utility for newly diagnosed patients is ongoing and will be presented at the meeting.
Yuan Yao, MD, MS: No relevant conflicts of interest to declare.